Floatz logo

Fezolinetant

Metastatic Prostate Carcinoma

Shehzad Basaria, M.D.Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

228 Active assets in the Metastatic Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
AXUMIN
VA Greater Los Angeles Healthcare System
Phase 4BBB
Leuporelin
Mayo Clinic
Phase 4BBB
Abiraterone
Mayo Clinic
Phase 4BB
Prednisone
Mayo Clinic
Phase 4BB
Pembrolizumab
CuraCell TX AB
Phase 2BB

View all 50 →

Same molecule, other indications

Fezolinetant is also rated in:

prostate adenocarcinomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →
breast cancerActive
CCC
Indicative · Phase 2
53 / 100
View asset →
prostate carcinomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →